{{Chembox
| ImageFile = Dalcetrapib.svg
| ImageSize =
| IUPACName = ''S''-[2-({[1-(2-Ethylbutyl)cyclohexyl]<wbr />carbonyl}amino)phenyl]<wbr />-2-methylpropanethioate
| OtherNames =

| Section1 = {{Chembox Identifiers
| CASNo = 211513-37-0
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3D050LIQ3H
| PubChem = 6918540
| ChemSpiderID = 5293737
| KEGG = D09708
| ChEMBL = 313006
| SMILES = O=C(Sc1ccccc1NC(=O)C2(CC(CC)CC)CCCCC2)C(C)C
| InChI = 1/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)
| InChIKey = YZQLWPMZQVHJED-UHFFFAOYAR
| StdInChI = 1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)
| StdInChIKey = YZQLWPMZQVHJED-UHFFFAOYSA-N 
| SMILES2 = CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
  }}

| Section2 = {{Chembox Properties
| Formula = C<sub>23</sub>H<sub>35</sub>NO<sub>2</sub>S
| MolarMass = 389.5945
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}

| Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
}}

'''Dalcetrapib''' (INN,<ref name="INN">{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 58 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL58.pdf | publisher = World Health Organization | accessdate = 3 January 2017 | pages = 250–1}}</ref> codenamed '''JTT-705''') is a [[CETP inhibitor]] which was being developed by [[Hoffmann–La Roche]] until May 2012.<ref name=pmid12444911/><ref name=bennett2012/>  The drug was aimed at raising the blood levels of "[[good cholesterol]]" (cholesterol carried in HDL particles, ''aka'' HDL-C).<ref name=cortez2012/>  Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health.<ref name=NIH2011/>

A 24-week [[clinical trial]] showed that dalcetrapib did increase HDL-C levels, supporting the agent's desired effect.<ref name=Roth2010/>  Further, the dal-PLAQUE phase IIb trial found evidence of [[Atheroma|plaque]] reduction.<ref name=fayad2011/>  Plaque reduction is an anticipated observation following an increase in HDL.{{citation needed|date=November 2012}}

{{As of|2010}} five phase II trials had started and there was no evidence of the raised blood pressure seen with [[torcetrapib]].<ref name=Roth2010/>

dal-VESSEL phase IIb trial found no evidence of flow-mediated dilatation improvement.  A 17% increase of [[Lipoprotein-associated phospholipase A2|Lp-PLA<sub>2</sub>]] mass level was noted.<ref name=tfl2012/>  Lp-PLA<sub>2</sub> is associated with [[coronary heart disease]] and [[stroke]].{{citation needed|date=November 2012}}

dal-OUTCOMES phase III trial passed its first interim review in July, 2011,<ref name=parziale/> however, development was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy.”.<ref name=bennett2012/>

The results of dal-OUTCOMES III were published in November, 2012.<ref>{{Cite journal 
| last1 = Schwartz | first1 = G. G. 
| last2 = Olsson | first2 = A. G. 
| last3 = Abt | first3 = M. 
| last4 = Ballantyne | first4 = C. M. 
| last5 = Barter | first5 = P. J. 
| last6 = Brumm | first6 = J. 
| last7 = Chaitman | first7 = B. R. 
| last8 = Holme | first8 = I. M. 
| last9 = Kallend | first9 = D. 
| last10 = Leiter 
| doi = 10.1056/NEJMoa1206797 | first10 = L. A. 
| last11 = Leitersdorf | first11 = E. 
| last12 = McMurray | first12 = J. J. V. 
| last13 = Mundl | first13 = H. 
| last14 = Nicholls | first14 = S. J. 
| last15 = Shah | first15 = P. K. 
| last16 = Tardif | first16 = J. C. 
| last17 = Wright | first17 = R. S. 
| last18 = Dal-Outcomes | first18 = I. 
| title = Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome 
| journal = New England Journal of Medicine 
| volume = 367 
| issue = 22 
| pages = 2089–2099 
| year = 2012 
| pmid = 23126252 
| pmc = 
}}</ref>

A pharmacogenomic [[genome-wide association study]] (GWAS) reported that patients from the dal-OUTCOMES study bearing a protective allele at SNP rs1967309 in the ADCY9 gene may have benefited from dalcetrapib therapy.<ref>{{Cite journal|last=Tardif|first=Jean-Claude|last2=Rhéaume|first2=Eric|last3=Lemieux Perreault|first3=Louis-Philippe|last4=Grégoire|first4=Jean C.|last5=Feroz Zada|first5=Yassamin|last6=Asselin|first6=Géraldine|last7=Provost|first7=Sylvie|last8=Barhdadi|first8=Amina|last9=Rhainds|first9=David|date=2015-04-01|title=Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib|journal=Circulation: Cardiovascular Genetics|volume=8|issue=2|pages=372–382|doi=10.1161/CIRCGENETICS.114.000663|issn=1942-3268|pmid=25583994}}</ref> Changes in inflammation and cholesterol efflux capacity may in part explain the benefits associated with the protective genotype.<ref>{{Cite journal|last=Tardif|first=Jean-Claude|last2=Rhainds|first2=David|last3=Brodeur|first3=Mathieu|last4=Feroz Zada|first4=Yassamin|last5=Fouodjio|first5=René|last6=Provost|first6=Sylvie|last7=Boulé|first7=Marie|last8=Alem|first8=Sonia|last9=Grégoire|first9=Jean C.|date=2016-08-01|title=Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes|journal=Circulation: Cardiovascular Genetics|volume=9|issue=4|pages=340–348|doi=10.1161/CIRCGENETICS.116.001405|issn=1942-3268|pmc=4982759|pmid=27418594}}</ref> The Dal-GenE trial is currently validating these observations. This clinical trial is a randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular risk in patients with recent acute coronary syndrome bearing the protective genotype.<ref>{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT02525939|title=Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|access-date=2016-12-02}}</ref>

==See also==
* [[CETP inhibitor]]

==References==
{{reflist|2|refs=

<ref name=pmid12444911>{{cite journal |author=Huang Z |author2= Inazu A |author3=Nohara A |author4=Higashikata T |author5=Mabuchi H |title=Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia |journal=[[Clin. Sci.]] |volume=103 |issue=6 |pages=587&ndash;594 |date=December 2002 |pmid=12444911 |doi= |url=http://www.clinsci.org/cs/103/0587/cs1030587.htm }}</ref>

<ref name=bennett2012>{{cite news |author=Simeon Bennett |author2=Naomi Kresge |last-author-amp=yes |title=Roche Drops After Halting Cholesterol Drug Development |url=https://www.bloomberg.com/news/2012-05-07/roche-halts-testing-on-dalcetrapib-cholesterol-treatment-1-.html | work=Bloomberg}}</ref>

<ref name=cortez2012>{{Citation|author=Michelle Fay Cortez |publication-date=November 5, 2012 |title=Roche’s Good Cholesterol Drug Shows Negative Side Effects |magazine=[[Bloomberg Businessweek]] |url=http://www.businessweek.com/news/2012-11-05/roche-s-good-cholesterol-drug-shows-negative-side-effects |accessdate=November 6, 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20121108025333/http://www.businessweek.com/news/2012-11-05/roche-s-good-cholesterol-drug-shows-negative-side-effects |archivedate=November 8, 2012 |df= }}</ref>

<ref name=fayad2011>{{cite journal |author=Zahi A Fayad |author2=Venkatesh Mani |display-authors=1 |title=Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial |journal=[[The Lancet]] |volume=378 |issue=9802 |pages=1547&ndash;1559 |year=2011 |doi=10.1016/S0140-6736(11)61383-4 |url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61383-4/abstract }}</ref>

<ref name=NIH2011>{{cite web<!--statement lifted from [[High-density lipoprotein]]--> |title=NIH stops clinical trial on combination cholesterol treatment |url=http://www.nih.gov/news/health/may2011/nhlbi-26.htm |work=National Institute of Health |publisher=[[NHLBI]] |accessdate=June 2, 2011 }}</ref>

<ref name=parziale>{{cite web |author=Gail Parziale |title=Dalcetrapib and Anacetrapib: a Tale of Two CETPs |url=http://www.pharma-share.com/dalcetrapib-anacetrapib-tale-cetps |deadurl=yes |archiveurl=https://web.archive.org/web/20111219065313/http://www.pharma-share.com/dalcetrapib-anacetrapib-tale-cetps |archivedate=2011-12-19 |df= }}</ref>

<ref name=Roth2010>{{cite journal |doi=10.1093/eurheartj/ehp601 |author=Stein |url=http://eurheartj.oxfordjournals.org/content/31/4/480.full |journal=[[Eur. Heart J.]] |last2=Roth |first2=EM |last3=Rhyne |first3=JM |last4=Burgess |first4=T |last5=Kallend |first5=D |last6=Robinson |first6=JG |title=Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial |volume=31 |issue=4 |pages=480&ndash;4888 |year=2010 |pmid=20097702 |pmc=2821630 |display-authors=1 }}</ref>

<ref name=tfl2012>{{cite journal |author=Thomas F. Lüscher |author2=Stefano Taddei |display-authors=1 |title=Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial |journal=[[Eur. Heart J.]] |year=2012 |doi=10.1093/eurheartj/ehs019 |url=http://eurheartj.oxfordjournals.org/content/early/2012/02/16/eurheartj.ehs019.abstract |volume=33 |issue=7 |pages=857–865}}</ref>

}}

{{Lipid modifying agents}}

[[Category:Anilides]]
[[Category:Hoffmann-La Roche]]
[[Category:Thioesters]]